NCT07110610View on ClinicalTrials.gov

Phase 1 Single and Multiple Ascending Dose of LTG-321 in Healthy Participants

PHASE1RecruitingINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

September 3, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Healthy Participants
Interventions
DRUG

LTG-321

active investigational drug

OTHER

Placebo

Placebo-to-match LTG-321

Trial Locations (1)

Unknown

RECRUITING

New Zealand Clinical Research, Christchurch

Sponsors
All Listed Sponsors
lead

Latigo Biotherapeutics

INDUSTRY

NCT07110610 - Phase 1 Single and Multiple Ascending Dose of LTG-321 in Healthy Participants | Biotech Hunter | Biotech Hunter